News | May 27, 2026
Siegfried locks in CHF 200m bond deal as investors bet big on pharma outsourcing boom
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
Keeps Halo Pharma to drive independent growth
Workshop focused on strengthening sterile processing standards, infection prevention, and CSSD best practices in healthcare settings
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
The transaction marks a clear portfolio reshuffle for Indoco
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
Subscribe To Our Newsletter & Stay Updated
